Author

Peter Bossuyt 1

1 Imelda General Hospital,Bonheiden,Belgium

ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment

Joana Torres, Stefanos Bonovas, Glen A Doherty, Torsten Kucharzik, Javier Gisbert, Tim Raine, Michel Adamina, Alessandro Armuzzi, Oliver Bachmann, Palle Bager, Livia Biancone, Bernd Bokemeyer, Peter Bossuyt, Johan Burisch, Paul Collins, Alaa El-Hussuna, Pierre Ellul, Cornelia Frei-Lanter, Federica Furfaro, Christian Gingert, Paolo Gionchetti, Fernando Gomollón, Marien González-Lorenzo, Hannah Gordon, Tibor Hlavaty, Pascal Juillerat, Konstantinos H. Katsanos, Uri Kopylov, Eduards Krustins, Theodore Lytras, Christian Maaser, Fernando Jose Magro Dias, John K. Marshall, Pär Myrelid, Gianluca Pellino, Isadora Rosa, João Sabino, Edoardo Vincenzo Savarino, Antonino Spinelli, Laurents Stassen, Mathieu Uzzan, Stephan Vavricka, Bram Verstockt, Janindra Warusavitarne, Oded Zmora, Gionata Fiorino

DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: A SUBGROUP ANALYSIS OF THE CALM STUDY

Peter Bossuyt, Geert R. D'Haens, Remo Panaccione, William Sandborn, Walter Reinisch, Simon Travis, Stefan Schreiber, Alessandro Armuzzi, Silvio Danese, Sofie Berg, Joel Petersson, Jen-Fue Maa, Ezequiel Neimark, Jean-Frederic Colombel

Disease monitoring with biomarkers and endoscopy: How to best combine them?

Peter Bossuyt

CHARACTERISTICS OF CHILDREN WITH CROHN?S DISEASE FAILING SUSTAINED REMISSION DESPITE ANTI-TNF EXPOSURE

Lucas Wauters, Françoise Smets, Ilse Hoffman, Elisabeth De Greef, Patrick Bontems, Philippe Alliet, Wim Arts, Bruno Hauser, Stephanie Van Biervliet, Els Van de Vijver, Isabelle Paquot, Harald Peeters, Peter Bossuyt, Jean François Rahier, Tom Moreels, Olivier Dewit, Denis Franchimont, Vinciane Muls, Fernand Fontaine, Edou

HEALTH LITERACY, QUALITY OF LIFE, WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN YOUNG ADULTS WITH CROHN'S DISEASE COMPARED TO DIABETES MELLITUS PATIENTS: LONG-TERM FOLLOW-UP FROM THE BELGIAN CROHN'S DISEASE REGISTRY

Constance Carels, Lucas Wauters, Filip Baert, Peter Bossuyt, Bruno Hauser, Robert Hilbrands, Ilse Hoffman, Bart Keymeulen, An Outtier, Isabelle Paquot, Isabelle Ruytjens, Marc Simoens, Clara Thienpont, Annelies Verreth, Bram Verstockt, Severine Vermeire, Gigi Veereman

EARLY FIBROSTENOSIS IN CROHN’S DISEASE IS ASSOCIATED WITH MULTIPLE SUSCEPTIBILITY LOCI ON IMMUNOCHIP ANALYSIS

Tom Holvoet, Peter Bossuyt, Isabelle Cleynen, Isabelle De Kock, Pieter Hindryckx, Severine Vermeire, Debby Laukens, Martine De Vos

EARLY MUCOSAL HEALING IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB PREDICTS FAVORABLE OUTCOMES: DATA FROM THE REAL LIFE BE-SMART COHORT.

Peter Bossuyt, Filip Baert, Francois D’Heygere, Antoine Nakad, Edouard Louis, Fernand Fontaine, Denis Franchimont, Olivier Dewit, Philippe Van Hootegem, Stijn Vanden Branden, Guy Lambrecht, Marc Ferrante

Location but not severity of endoscopic lesions at baseline influences endoscopic healing rates in Crohn's disease patients treated with infliximab: a post-hoc analysis of the TAILORIX trial

Pauline Riviere, Geert R. D'Haens, Laurent Peyrin-Biroulet, Filip Baert, Guy Lambrecht, Benjamin Pariente, Peter Bossuyt, Anthony Buisson, Bas Oldenburg, Severine Vermeire, David Laharie

Long-term effect of risankizumab on improved and sustained health-related quality of life over 3 years in patients with moderate to severe Crohn's disease: interim analysis of a phase 2 open-label extension study

Edouard Louis, Peter Bossuyt, Julian Panés, Brian G. Feagan, Jasmina Kalabic, Kori Wallace, Naijun Chen, Wan-Ju Lee, Marc Ferrante

Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response

An Outtier, Jean François Rahier, Peter Bossuyt, Arnaud Colard, Denis Franchimont, Guy Lambrecht, Elisabeth Macken, Wouter Van Moerkercke, Filip Baert, Evelien Humblet, Philippe Van Hootegem, Ann Gils, Marc Ferrante, Severine Vermeire

Item 1 - 10 / 27
1
2 3
We use cookies in order to provide you with a better browsing experience. This includes third-party cookies for traffic analyzation purposes. See here for more information.
OK